A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is
How Does Interferon-Alpha Exert Its Antitumour Activity in Multiple Myeloma?
The interferons (IFNs) have become accepted therapy in a range of hematological and non-hematological malignancies. One malignancy where IFN has demonstrated antitumour activity is multiple myeloma, where monotherapy with IFN-a yields a response rate of around 15%. It has also been suggested that myeloma patients may bene® t from the addition of IFN-a in induction therapy and:or as maintenance treatment. The mechanism behind IFNs antitumour action in myeloma is, however, highly unclear. Thisdoi:10.1080/028418600750063532 pmid:11145436 fatcat:o64sakts5rgfnltzz5bcnrndpa